• (PLX AI) – Lundbeck has EBIT-margin expansion potential, analysts at DNB said, reiterating a buy recommendation on the stock.
  • • The Danish drugmaker has positive momentum, especially for Brintellix, but also Rexulti and Vyepti, DNB said
  • • Vyepti could represent significant value potential: DNB
  • • Price target cut to DKK 235 from DKK 250; Lundbeck currently trading at DKK 182.50

Quelle: PLX AI